Delivery Order SPE2DB24D3015-SPE2DB25FFZKM

Award Date 5/15/25
Potential Completion Date 5/16/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,632.54 contract is for the supply of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of March 26, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,742.80 contract is for the supply of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a diabetes medication. The delivery order has an ultimate completion date of April 28, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,499.81 contract is for the delivery of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a diabetes medication, with a performance period ending on May 6, 2025. The contract is not set-aside and was competed openly. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $13,842.89, is for the supply of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a diabetes medication. The contract has a period of performance through May 6, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,088.36, is for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a medication used for the treatment of diabetes. The contract has an ultimate completion date of April 24, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,265.08 contract is for the supply of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a diabetes medication. The order has a completion date of May 8, 2025 and is not set aside. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a...
This is a $2,176.72 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a diabetes medication, with a performance period through May 19, 2025. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical support...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,265.08 contract is for the supply of MOUNJARO 15 MG/0.5 ML PEN 0.5ML, a diabetes medication. The award has an ultimate completion date of April 18, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
This is a $6,361.20 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of MOUNJARO 2.5 MG/0.5 ML PEN 0.5ML, a medication used to treat diabetes. The contract has an ultimate completion date of November 1, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,632.54 firm fixed-price delivery order is for the supply of MOUNJARO 15 MG/0.5 ML PEN 0.5ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of November 15, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB24D3015
    Indefinite Delivery Contract
  • SPE2DB24D3015-SPE2DB25FFZKM
    Delivery Order

This is a $10,079.76 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of 4568263269 - MOUNJARO 15 MG/0.5 ML PEN 0.5ML, a diabetes treatment medication. The contract has an ultimate completion date of May 16, 2025.

AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This allows the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The contract award is not set-aside.

Generated 8/14/25, 9:44 AM